AnodyneWiki

Cabergoline

Cabergoline
Cabergoline
Molecular structure drawn from PubChem coordinates
Physical properties
[]
Molecular mass451.60 g/mol [1]
Melting point102-104 °C [1]
SolubilityInsoluble [1]
Predicted LogP3.4 [1]
Structural Identifiers
[]
Molecular formulaC26H37N5O2
IUPAC name(6aR,9R,10aR)-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)-7-prop-2-enyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
SMILESCCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(C1)CC=C
InChIInChI=1S/C26H37N5O2/c1-5-11-30-17-19(25(32)31(26(33)27-6-2)13-8-12-29(3)4)14-21-20-9-7-10-22-24(20)18(16-28-22)15-23(21)30/h5,7,9-10,16,19,21,23,28H,1,6,8,11-15,17H2,2-4H3,(H,27,33)/t19-,21-,23-/m1/s1
InChIKeyKORNTPPJEAJQIU-KJXAQDMKSA-N
CAS number81409-90-7
UNIILL60K9J05T
PubChem CID54746
Pharmacokinetics[]
Elimination half-life63–69 hours (estimated)
MetabolismLiver, predominately via hydrolysis of the acylurea bond or the urea moiety
ExcretionUrine (22%), feces (60%)
Routes of administrationOral

Cabergoline (also known as Dostinex, Cabaser, Cabergolina, Cabergolinum, Fce-21336, Velactis, Fce 21336, 1-((6-Allylergolin-8β-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea, 1-ethyl-3-(3'-dimethylamionpropyl)-2-(6'-allylergoline-8'β-carbonyl)urea or 1-[(6-allylergoline-8β-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethylurea) is a substance of the ergoline and lysergamide class.

Chemistry

 []

Cabergoline is a single defined stereoisomer.

Cabergoline matches Lipinski's rule of five.

Pharmacology

Mechanism of action []

The dopamine D<sub>2</sub> receptor is a 7-transmembrane G-protein coupled receptor associated with G<sub>i</sub> proteins. In lactotrophs, stimulation of dopamine D<sub>2</sub> causes inhibition of adenylyl cyclase, which decreases intracellular cAMP concentrations and blocks IP3-dependent release of Ca<sup>2+</sup> from intracellular stores. Decreases in intracellular calcium levels may also be brought about via inhibition of calcium influx through voltage-gated calcium channels, rather than via inhibition of adenylyl cyclase. Additionally, receptor activation blocks phosphorylation of p42/p44 MAPK and decreases MAPK/ERK kinase phosphorylation. Inhibition of MAPK appears to be mediated by c-Raf and B-Raf-dependent inhibition of MAPK/ERK kinase. Dopamine-stimulated growth hormone release from the pituitary gland is mediated by a decrease in intracellular calcium influx through voltage-gated calcium channels rather than via adenylyl cyclase inhibition. Stimulation of dopamine D<sub>2</sub> receptors in the nigrostriatal pathway leads to improvements in coordinated muscle activity in those with movement disorders. Cabergoline is a long-acting dopamine receptor agonist with a high affinity for D2 receptors. Receptor-binding studies indicate that cabergoline has low affinity for dopamine D1, &alpha;<sub>1</sub>,- and &alpha;<sub>2</sub>- adrenergic, and 5-HT<sub>1</sub>- and 5-HT<sub>2</sub>-serotonin receptors. [1]

Interactions []

Interaction mechanisms documented in (number of interacting drugs):

shared target150
metabolism / induction / inhibition106 (1 contraindicated)
shared target1

Medical side effects []

124 side effects listed on drug labels in (cabergoline).

  • Nausea
  • Headache
  • Dizziness
  • Syncope
  • Lightheadedness
  • Constipation
  • Hyperhidrosis
  • Dyskinesia
  • Influenza
  • Gastritis
  • Asthenia
  • Fatigue
  • Hallucination
  • Sleep disorder
  • Bronchitis
  • Back pain
  • Urinary tract infection
  • Abdominal pain
  • Gastrointestinal pain
  • Hypertension
  • Oedema peripheral
  • Dyspepsia
  • Upper respiratory tract infection
  • Euphoric mood
  • Hypokinesia
  • Nightmare
  • Pneumonia
  • Confusional state
  • Feeling abnormal
  • Malaise
  • Vertigo
  • Vomiting
  • Arthropathy
  • Osteoarthritis
  • Orthostatic hypotension
  • Prostatic disorder
  • Depression
  • Pain
  • Diarrhoea
  • Breast pain
  • Breast pain female
  • Paraesthesia
  • Dry mouth
  • Somnolence
  • Excessive daytime sleepiness
  • Nervousness
  • Tension
  • Palpitations
  • Flatulence
  • Hypotension
  • Hypotensive
  • Hypotension symptomatic
  • Decreased appetite
  • Anxiety
  • Insomnia
  • Shock
  • Loss of consciousness
  • Menopausal symptoms
  • Hot flush
  • Dysmenorrhoea
  • Pruritus
  • Gravitational oedema
  • Arthralgia
  • Musculoskeletal discomfort
  • Rhinitis
  • Disturbance in attention
  • Mental disability
  • Visual impairment
  • Periorbital oedema
  • Acne
  • Toothache
  • Discomfort
  • Ill-defined disorder
  • Influenza like illness
  • Throat irritation
  • Aggression
  • Alopecia
  • Delusion
  • Dyspnoea
  • Oedema
  • Dermatitis
  • Rash
  • Fibrosis
  • Cardiac valve disease
  • Hypersensitivity
  • Impulse-control disorder
  • Libido increased
  • Disturbance in sexual arousal
  • Muscle spasms
  • Pathological gambling
  • Pericardial effusion
  • Pericarditis
  • Pleural effusion
  • Pleurisy
  • Psychotic disorder
  • Pulmonary fibrosis
  • Retroperitoneal fibrosis
  • Vasospasm
  • Hepatic function abnormal
  • Liver function test abnormal
  • Blood creatinine increased
  • Hypersexuality
  • Respiratory failure
  • Regurgitation
  • Pleural fibrosis
  • Congenital anomaly
  • Developmental delay
  • Arrhythmia
  • Neoplasm malignant
  • Duodenal ulcer
  • Epistaxis
  • Cardiac disorder
  • Cardiac failure
  • Hemianopia
  • Musculoskeletal pain
  • Nasal congestion
  • Pericarditis constrictive
  • Congenital genitourinary abnormality
  • Weight increased
  • Weight decreased
  • Abdominal pain upper
  • Abdominal discomfort
  • Face oedema
  • Sudden onset of sleep

Indications

  • Amenorrhoea
  • Anovulation
  • Breast feeding
  • Cleft lip
  • Death neonatal
  • Empty sella syndrome
  • Galactorrhoea
  • Hyperprolactinaemia
  • Mental disorder
  • Oligomenorrhoea
  • Parkinson's disease
  • Pituitary adenoma
  • Pituitary tumour
  • Prolactinoma
  • Stillbirth

 []

  • Australia: Cabergoline is a Schedule 4.[3]
  • United States: Cabergoline is Prescription only.

See also []

External links []

References []

  1. National Center for Biotechnology Information. PubChem Compound Summary for CID 54746, Cabergoline. Accessed November 20, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/54746
  2. U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Cabergoline. UNII: LL60K9J05T. Global Substance Registration System. Accessed November 20, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/LL60K9J05T
  3. Carbelin (Nova Pharmaceuticals Australasia Pty Ltd). Therapeutic Goods Administration (TGA). 13 September 2024. https://www.tga.gov.au/resources/prescription-medicines-registrations/carbelin-nova-pharmaceuticals-australasia-pty-ltd

Data sources []

SourceStatusUpdated (UTC)
dosingmissing (no dosing statistics)2026-11-20 03:05:44
drugspromissing (no DrugsPRO reagent data)2026-11-20 03:05:40
erowidmissing (no Erowid substance of that name)2026-11-20 03:05:40
gsrsok2026-11-20 03:05:40
hmdbmissing (hmdb.ca refused automated access to HMDB0014393)2026-11-20 03:05:40
keggok2026-11-20 03:05:42
pubchemok2026-11-20 03:05:40
redditmissing (no r/tripreports posts mention it)2026-11-20 03:05:40
siderok2026-11-20 03:05:40
structureok2026-11-20 03:05:40
wikipediaok2026-11-20 03:05:40